{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:54:38Z","timestamp":1792760078713,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13318-025-00936-5","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T14:16:45Z","timestamp":1738419405000},"page":"161-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dosage Recommendations for Off-label Use of Mycophenolate Mofetil in Pediatric Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation: An Approach Based on Population Pharmacokinetic Studies"],"prefix":"10.1007","volume":"50","author":[{"given":"Lu-lu","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-920X","authenticated-orcid":false,"given":"Tao-tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"936_CR1","first-page":"29","volume":"37","author":"TBLP Cooley","year":"1925","unstructured":"Cooley TBLP. A series of cases of splenomegaly in children with anemia and peculiar bone changes [J]. Trans Am Pediatr Soc. 1925;37:29\u201330.","journal-title":"Trans Am Pediatr Soc"},{"issue":"4","key":"936_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MPH.0000000000000327","volume":"37","author":"AA Adly","year":"2015","unstructured":"Adly AA, Ebeid FS. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt[J]. J Pediatr Hematol Oncol. 2015;37(4):281\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"936_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/03630269.2014.880715","volume":"38","author":"WY Au","year":"2014","unstructured":"Au WY, Li Cf Fang JP, et al. Assessment of iron overload in very young children with limited thalassemia care resources in South China[J]. Hemoglobin. 2014;38(2):119\u201326.","journal-title":"Hemoglobin"},{"issue":"5","key":"936_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1586\/14737167.2014.927314","volume":"14","author":"TA Lee","year":"2014","unstructured":"Lee TA, von Riedemann S, Tricta F. Cost-utility of chelators in transfusion-dependent \u03b2-thalassemia major patients: a review of the pharmacoeconomic literature[J]. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):651\u201360.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"936_CR5","first-page":"224","volume":"10","author":"M Seyedifar","year":"2016","unstructured":"Seyedifar M, Dorkoosh FA, Hamidieh AA, et al. Health-related quality of life and health utility values in beta thalassemia major patients receiving different types of iron chelators in Iran[J]. Int J Hematol OncolStem Cell Res. 2016;10(4):224\u201331.","journal-title":"Int J Hematol OncolStem Cell Res"},{"issue":"5","key":"936_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/trf.13513","volume":"56","author":"D Weidlich","year":"2016","unstructured":"Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing \u03b2-thalassemia major over 50 years in the United Kingdom[J]. Transfusion. 2016;56(5):1038\u201345.","journal-title":"Transfusion"},{"key":"936_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00007691-200002000-00004","volume":"22","author":"M Oellerich","year":"2000","unstructured":"Oellerich M, Shipkova M, Sch\u00fctz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring [J]. Ther Drug Monit. 2000;22:20\u20136.","journal-title":"Ther Drug Monit"},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0009-9120(99)00101-0","volume":"33","author":"E Wieland","year":"2000","unstructured":"Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?[J]. Clin Biochem. 2000;33:107\u201313.","journal-title":"Clin Biochem"},{"issue":"6","key":"936_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil[J]. Clin Pharmacokinetics. 1998;34(6):429\u201355.","journal-title":"Clin Pharmacokinetics"},{"issue":"7","key":"936_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bmt.1704647","volume":"34","author":"B Bolwell","year":"2004","unstructured":"Bolwell B, Sobecks R, Pohlman B, Andresen S, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation[J]. Bone Marrow Transplant. 2004;34(7):621\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"936_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJM199310213291703","volume":"329","author":"NJ Chao","year":"1993","unstructured":"Chao NJ, Schmidt Gm-Niland JC, Niland JC, Amylon MD, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease[J]. N Engl J Med. 1993;329(17):1225\u201330.","journal-title":"N Engl J Med"},{"issue":"7","key":"936_CR12","first-page":"2303","volume":"92","author":"V Ratanatharathorn","year":"1998","unstructured":"Ratanatharathorn V, Nash R, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation[J]. Blood. 1998;92(7):2303\u201314.","journal-title":"Blood"},{"issue":"4","key":"936_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/00007890-199902270-00001","volume":"67","author":"M Bornh\u00e4user","year":"1999","unstructured":"Bornh\u00e4user M, Schuler U, P\u00f6rksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation[J]. Transplantation. 1999;67(4):499\u2013504.","journal-title":"Transplantation"},{"issue":"4","key":"936_CR14","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"D Niederwieser","year":"2003","unstructured":"Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases[J]. Blood. 2003;101(4):1620\u20139.","journal-title":"Blood"},{"issue":"3","key":"936_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0009-9120(00)00053-9","volume":"33","author":"MG Kiehl","year":"2000","unstructured":"Kiehl MG, Shipkova M, Basara N, et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite[J]. Clin Biochem. 2000;33(3):203\u20138.","journal-title":"Clin Biochem"},{"issue":"3","key":"936_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1034\/j.1399-0012.2001.150306.x","volume":"15","author":"A Jenke","year":"2001","unstructured":"Jenke A, Renner U, Richte M, et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation[J]. Clin Transplant. 2001;15(3):176\u201384.","journal-title":"Clin Transplant"},{"issue":"5","key":"936_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bmt.1703633","volume":"30","author":"M Baudard","year":"2002","unstructured":"Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients[J]. Bone Marrow Transplant. 2002;30(5):287\u201395.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"936_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","volume":"40","author":"K Chen","year":"2018","unstructured":"Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit. 2018;40(6):663\u201374.","journal-title":"Ther Drug Monit"},{"issue":"17","key":"936_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area[J]. N Engl J Med. 1987;317(17):1098.","journal-title":"N Engl J Med"},{"issue":"4","key":"936_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1046\/j.1523-1755.2003.00208.x","volume":"64","author":"A Pierrat","year":"2003","unstructured":"Pierrat A, Gravier E, Saunders C, et al. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas[J]. Kidney Int. 2003;64(4):1425\u201336.","journal-title":"Kidney Int"},{"issue":"6","key":"936_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40262-022-01108-3","volume":"61","author":"F Zhang","year":"2022","unstructured":"Zhang F, Chen X, Wu T, et al. Population pharmacokinetics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation: a prospective multicenter study[J]. Clin Pharmacokinet. 2022;61(6):881\u201393.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"936_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies[J]. J Pharmacokinet Pharmacodyn. 2007;34(5):711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"936_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology[J]. Ther Drug Monit. 2021;43(2):150\u2013200.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"936_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bbmt.2005.03.006","volume":"11","author":"RA Nash","year":"2005","unstructured":"Nash RA, Johnston L, Parker P, et al. A phase I\/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant. 2005;11(7):495\u2013505.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"936_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13318-016-0378-6","volume":"42","author":"D Zhang","year":"2017","unstructured":"Zhang D, Chow DS. Clinical pharmacokinetics of mycophenolic acid in hematopoietic stem cell transplantation recipients[J]. Eur J Drug Metab Pharmacokinet. 2017;42(2):183\u20139.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"936_CR26","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/0091270011422814","volume":"52","author":"H Kim","year":"2012","unstructured":"Kim H, Long-Boyle J, Rydholm N, et al. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation[J]. J Clin Pharmacol. 2012;52(11):1665\u201375.","journal-title":"J Clin Pharmacol"},{"key":"936_CR27","unstructured":"Yaffe S, Aranda JV, Kauffman RE. Neonatal and pediatric pharmacology: therapeutic principles in practice, 3rd edn, chapter 3. Lippincott Williams & Wilkins, Philadelphia, pp. 20-31."},{"issue":"2","key":"936_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","volume":"21","author":"N Chen","year":"2006","unstructured":"Chen N, Aleksa K, Woodland C, et al. Ontogeny of drug elimination by the human kidney[J]. Pediatr Nephrol. 2006;21(2):160\u20138.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"936_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2125.2010.03734.x","volume":"70","author":"L Zeng","year":"2010","unstructured":"Zeng L, Blair E, Nath CE, et al. Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation[J]. Br J Clin Pharmacol. 2010;70(4):567\u201379.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"936_CR30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/bcp.12426","volume":"78","author":"M Dong","year":"2014","unstructured":"Dong M, Fukuda T, Cox S, et al. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period[J]. Br J Clin Pharmacol. 2014;78(5):1102\u201312.","journal-title":"Br J Clin Pharmacol"},{"key":"936_CR31","doi-asserted-by":"publisher","first-page":"1002628","DOI":"10.3389\/fphar.2022.1002628","volume":"13","author":"Y Wei","year":"2022","unstructured":"Wei Y, Wu D, Chen Y, et al. Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation[J]. Front Pharmacol. 2022;13:1002628.","journal-title":"Front Pharmacol"},{"key":"936_CR32","unstructured":"CHEN shiwei, YE zhicheng, FU pan, et al. Reference ranges of biochemical determination items for children's kidney function in Shanghai. [J] Laboratory Medicine. 2018; 33: 884\u2013887. https:\/\/link.cnki.net\/urlid\/1631.1915.R.20181029.20181406.20181006. CNKI."},{"issue":"7","key":"936_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/00912709922008353","volume":"39","author":"B Kaplan","year":"1999","unstructured":"Kaplan B, Meier-Kriesche H, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding[J]. J Clin Pharmacol. 1999;39(7):715\u201320.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"936_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","volume":"46","author":"CE Staatz","year":"2007","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet. 2007;46(1):13\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"936_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbmt.2015.09.014","volume":"22","author":"HM Chaudhry","year":"2016","unstructured":"Chaudhry HM, Bruce AJ, Wolf RC, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review[J]. Biol Blood Marrow Transplant. 2016;22(4):605\u201316.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"936_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/FTD.0b013e31803111d5","volume":"29","author":"R Borrows","year":"2007","unstructured":"Borrows R, Chusney G, Loucaidou M, et al. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation[J]. Ther Drug Monit. 2007;29(1):122\u20136.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"936_CR37","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/bcp.13850","volume":"85","author":"HX Zhang","year":"2019","unstructured":"Zhang HX, Sheng CC, Liu LS, et al. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus[J]. Br J Clin Pharmacol. 2019;85(4):746\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"936_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/jcph.14","volume":"53","author":"H Li","year":"2013","unstructured":"Li H, Mager D, Sandmaier BM, et al. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil[J]. J Clin Pharmacol. 2013;53(4):393\u2013402.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"936_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2125.2012.04372.x","volume":"75","author":"A Frymoyer","year":"2013","unstructured":"Frymoyer A, Verotta D, Jacobson P, et al. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors[J]. Br J Clin Pharmacol. 2013;75(2):463\u201375.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"936_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/bmt.2017.213","volume":"53","author":"K Yoshimura","year":"2018","unstructured":"Yoshimura K, Yano I, Yamamoto T, et al. Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation[J]. Bone Marrow Transplant. 2018;53(1):44\u201351.","journal-title":"Bone Marrow Transplant"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00936-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:15:35Z","timestamp":1741194935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00936-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00936-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"22 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients in this study have signed informed consent forms and agreed that their data can be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Tao-tao Liu designed the research. Lu-lu Niu, Yong-jun Liu, Yun Wu, Tian-min Huang, Ting-qing Wu, Yang Xiao, Xin Chen, Yi-lin Luo, collected and reviewed the data for this study. Lu-lu Niu establishing the PPK model and the simulation of the dosing regimens. Lu-lu Niu wrote the manuscript. All authors contributed to the interpretation of the results, the reviewing of the manuscript, and the decision to submit this manuscript to be published. All authors read and approved the final manuscript. All authors agreed to publish this work","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The data and code that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and Code Availability"}},{"value":"The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved the protocol (NO.2023-K130-01). This study complied with the Declaration of Helsinki and national and institutional standards. And all recruited patients, and their guardians signed the informed consent form before participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All patients and their guardians had signed informed consent before the study began.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declared no conflicts of interest concerning the research, authorship, and publication of this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No funding was received for this work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}